It is a similar market day as earlier this week with some definite movers to the upside and downside but with nothing that is general to the sector. If anything it is slightly weaker than the market at large but not in any dramatic sense. Sector seems more driven by stock specific stories rather than […]
ASH 2013 Preview on Lymphoid Malignancies
This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking the biotech sector’s run the past 2 years. They are now within months of receiving approval for 2 indications where they could benefit patient lives […]
October 11- Morning note
Well, we have three straight days of interesting news with ECYT rounding out the week. I want to focus on that today and get this out earlier than usual as this could be actionable today. 1. Before diving into ECYT, GS was out with a report on PCYC where they raised their price target to […]
October 10-EOD
Macro, macro, macro but now it is to the other way. We did have another big piece of news hit last night in terms of CLL, which I will talk about for today’s note. 1. The news of the day (or actually last night) was the halting of the GILD idelalisib trial of previously treated […]
October 8- Mid Day
While I wanted some more news from the biotech sector this was not exactly what I was planning. I discuss my thoughts on ARIA in an article on the street, so I will not belabor it more here. There are a couple of broader points that I think are interesting in light on today’s action. […]
October 7- EOD
Macro, macro, and more macro. That seems to be driving the market and without any significant biotech specific news that was the word of the day. As we get closer to the debt ceiling the greater the headwind and the closer correlation between stock movements will get to 1. Biotechs will be particularly vulnerable given […]
October 4- EOD
It green morning with biotechs taking part in the early rally and showing perhaps some minor strength but nothing earth shattering. Again it was a relatively quiet day on the news front, so I will do a couple of quick hitters today. 1. PCYC got another positive sell side report. I think we are clearly […]
October 2- EOD
Some macro weakness today but biotechs seemed to hold up fairly well. While most were red, it did not seem to be overdone to the downside. Plus, there were some pockets of green. All in all, not a great day to be in biotechs but it could have been worse given the broader market. The […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 26-EOD
It was an interesting news day and biotechs even participated in the market strength today, which has not happened in a little while. I would not call the biotech action strong from a relative performance sense but it is encouraging to see them at least perform in line with the broader market. 1. Lilly(LLY) announced […]
September 25- EOD
A very interesting and odd day in the market today. Overall the market continued its weakness and biotechs were generally down. The market came back and it seemed to turn into a chop fest. I suspected that the CLVS news would have had a more negative impact on biotech sentiment but there did not seem […]
September 17- EOD
Not a lot of stock specific news but some interesting larger biotech developments. The market held up better than I thought given yesterday’s close and biotechs seemed like slight underperformers but not to the same degree as yesterday. That being said I think the CLVS news seemed to bring in some buyers, so they ended […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 4- EOD
There was some nice action in biotech land today despite not being particularly busy in terms of news. There was some interesting stock specific action and the sector was a mixed bag. Stocks without specific news tended to underperform but not universally so. The next couple of months will be interesting as volume will likely […]
August 29- EOD
We got a trickle of some interesting biotech news but still nothing dramatic. I suspect that the pace will increase in September as the summer ends and the fall healthcare conference season begins. 1. PCYC announced the acceptance of the NDA for previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small […]
August 12- EOD
It looks like we are setting up to have a week of data releases with VICL today and perhaps both GTXI and MNKD later this week. It should generate some interest but none of these will likely affect biotech sentiment writ large, so they should remain stock specific stories. That being said it looks like […]
